The impact of clinicopathological parameters and the expression of HER-2 proteins on the survival of gastric cancer patients

Edina Lazović Salčin, Mirsad Dorić, Nina Čamdžić, Suada Kuskunović-Vlahovljak, Svjetlana Radović, Mirsad Babić


Objective: Many studies offer controversial data related to factors that influance prognosis in gastric cancer. The aim of this study was to investigate impact ofclinicopathological parameters and expression of HER-2 proteins on survival in gastric carcinoma.

Methods: Tissue samples of 50 patients with Billroth II surgery resection were selected for this pathological condition at the Department of Pathology, School of Medicine, University of Sarajevo. Clinical and morphological data for each case were classified and interpreted according to the evaluation protocol recommended by the American Joint Committee of Cancer (AJCC) and International Union against Cancer (IUCC). HER-2 protein expression was assessed by immunohistochemical staining.

Results: There was significant difference in survival distributions for the grade 1 vs 2, χ2(1)=8.852, p=0.003, grade 1 vs 3, χ2(1)=7.131, p=0.008, and grade 1 vs 4, χ2(1)=8.284, p=0.004.The survival distributions for the pT stages were significantly different, χ2(3)=8.744, p<0.05. There was a statistically significant difference in survival distributions for the pT2 vs. pT3 stage, χ2(1)=6.595, p=0.010.The survival distributions for the four pN stages were statistically significantly different, χ2(3)=11.468, p<0.01. There was a statistically significant difference in survival distributions for the pN0 stage vs. pN3 stage χ2(1)=7.449, p= 0.006. There was no statistically significant difference in survival between patients with HER-2 positive and HER-2 negative tumors (p>0.05).

Conclusion: Results of our study confirmed the significance of standard clinicopathological parameters as prognostic factors in term of overall survival. HER-2 expression was not found as significant prognostic factor of survival.

Keywords: gastric cancer, clinicopathological paramteres, HER-2,survival

Full Text:



Apicella M, Corso S, Giordano S. Targeted therapies for gastric cancer: failures and hopes from clinical trials. Oncotarget 2017;8(34):57654-57669.

Chua TC, Merrett ND. Clinicopathologic factors associated with HER2-positive gastric cancer and its impact on survival outcomes--a systematic review. Int J Cancer 2012;130(12):2845-56.

Carcas LP. Gastric cancer review. Journal of Carcinogenesis 2014;13:14.

Lei Y, Huang J, Zhao Q, Jiang N, Xu H, Wang Z, et al. The clinicopathological parameters and prognostic significance of HER2 expression in gastric cancer patients: a meta-analysis of literature. World Journal of Surgical Oncology 2017;15:68.

Sakai K, Mori S, Kawamoto T et al. Expression of epidermal growth factor receptors on normal human gastric epithelia and gastric carcinomas. J Natl Cancer Inst1986;77: 1047–52.

Park DI, Yun JW, Park JH, Oh SJ, Kim HJ, Cho YK, et al. HER-2/neu amplification is an independent prognostic factor in gastric cancer. Dig Dis Sci 2006; 51:1371-1379.

Grabsch H, Sivakumar S, Gray S, GabbertHE, Mu¨ller W. HER2 expression in gastric cancer: Rare, heterogeneous and of no prognostic value- conclusions from 924 cases of two independent series. Cell Oncol2010;32:57–65.

Kim KC, Koh YW, Chang HM, Kim TH, Yook JH, Kim BS, et al. Evaluation of HER2 protein expression in gastric carcinomas: comparative analysis of 1,414 cases of whole-tissue sections and 595 cases of tissue microarrays. Ann Surg Oncol 2011; 18:2833-2840.

Uprak TK, Attaallah W, Çelikel ÇA, Ayranci G, Yeğen C. HER-2 incidence in gastric cancer, its association with prognosis and clinicopathological parameters. Ulus Cerrahi Derg2015;31(4):207-13.

Bang Y-J, Van Cutsem E, Feyereislova A,Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastrooesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010;376:687–97.

Derek CA. Histopathology Reporting. 2nd ed. Springer; 2006.

Hu B, El Hajj N, Sittler S, Lammert N, Barnes R, Meloni-Ehrig A. Gastric cancer: Classification, histology and application of molecular pathology. Journal of Gastrointestinal Oncology 2012;3(3):251-261.

Washington K. 7th Edition of the AJCC Cancer Staging Manual: Stomach. Ann Surg Oncol 2010; 17:3077–3079.

Derek CA. Histopathology Reporting. 3rd ed. Springer; 2013.

Li C, Oh SJ, Kim S, Hyung WJ, Yan M, Zhu ZG, Noh SH. Macroscopic Borrmann type as a simple prognostic indicator in patients with advanced gastric cancer. Oncology2009;77(3-4):197-204

Yu GZ, Chen Y, Wang JJ. Overexpression of Grb2/HER2 signaling in Chinese gastric cancer: their relationship with clinicopathological parameters and prognostic significance. J Cancer Res Clin Oncol 2009;135:1331-1339.

Lazović Salčin E, Dorić M, Radović S, Babić M, Kuskunović S, Hukić A. HER2 protein expression in invasive gastric carcinoma. Folia Medica 2013;48(1):19-25.

Lee HR, Kim JH, Uhm HD, Ahn JB, Rha SY, Cho JY, et al. Overexpression of c-ErbB-2 protein in gastric cancer by immunohistochemical stain. Oncology 1996;53:192-197.

Vizoso FJ, Corte MD, Alvarez A, Garcia I, del Cesar JM, Bongera M, et al. Membranous levels of c-erbB-2 oncoprotein in gastric cancer: their relationship with clinicopathological parameters and their prognostic significance. Int J Biol Markers 2004;19:268–74.


  • There are currently no refbacks.